Arbutus Biopharma Corp. (ABUS)
5.095
+0.02
(+0.30%)
USD |
NASDAQ |
Sep 01, 16:00
5.095
0.00 (0.00%)
After-Hours: 17:09
Arbutus Biopharma Cash from Investing (Quarterly) : -1.664M for June 30, 2026
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -1.664M |
| March 31, 2026 | 2.199M |
| December 31, 2025 | -1.588M |
| September 30, 2025 | -10.23M |
| June 30, 2025 | 16.09M |
| March 31, 2025 | 11.35M |
| December 31, 2024 | 12.97M |
| September 30, 2024 | -11.87M |
| June 30, 2024 | 9.677M |
| March 31, 2024 | 11.69M |
| December 31, 2023 | 21.65M |
| September 30, 2023 | 10.48M |
| June 30, 2023 | 1.505M |
| March 31, 2023 | 16.68M |
| December 31, 2022 | 14.21M |
| September 30, 2022 | -12.48M |
| June 30, 2022 | -13.53M |
| March 31, 2022 | -60.06M |
| December 31, 2021 | -8.072M |
| September 30, 2021 | 16.31M |
| June 30, 2021 | -39.07M |
| March 31, 2021 | 18.22M |
| December 31, 2020 | -50.89M |
| September 30, 2020 | 14.88M |
| June 30, 2020 | 23.07M |
| Date | Value |
|---|---|
| March 31, 2020 | -2.401M |
| December 31, 2019 | -59.33M |
| September 30, 2019 | 17.04M |
| June 30, 2019 | 9.747M |
| March 31, 2019 | 61.03M |
| December 31, 2018 | 44.11M |
| September 30, 2018 | 11.92M |
| June 30, 2018 | 15.59M |
| March 31, 2018 | -75.67M |
| December 31, 2017 | 0.0792M |
| September 30, 2017 | 6.692M |
| June 30, 2017 | -1.557M |
| March 31, 2017 | 23.20M |
| December 31, 2016 | 3.151M |
| September 30, 2016 | 0.6019M |
| June 30, 2016 | -88.59M |
| March 31, 2016 | -13.58M |
| December 31, 2015 | -1.698M |
| September 30, 2015 | -18.29M |
| June 30, 2015 | -10.20M |
| March 31, 2015 | 37.55M |
| December 31, 2014 | 2.345M |
| September 30, 2014 | -0.3007M |
| June 30, 2014 | -43.49M |
| March 31, 2014 | -0.335M |
Cash From Investing Definition
Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Moderna, Inc. | 329.00M |
| Insmed, Inc. | 24.51M |
| Pfizer Inc. | 2.106B |
| Gossamer Bio, Inc. | 42.70M |
| Legend Biotech Corp. | -120.10M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -5.952M |
| Cash from Financing (Quarterly) | 3.079M |
| Free Cash Flow | -24.13M |
| Free Cash Flow Per Share (Quarterly) | -0.0301 |
| Free Cash Flow to Equity (Quarterly) | -5.668M |
| Free Cash Flow to Firm (Quarterly) | -5.934M |
| Free Cash Flow Yield | -2.44% |